Xvivo Perfusion: Redeye: Xvivo Perfusion - Harvest Season is Coming

We have conducted a survey to transplant physicians I the United
States and Europe. Results indicate a high potential for warm
perfusion. In light of the survey results and a deeper analysis of
the newly formed collaboration with United Therapeutics, we forecast
a slightly faster adaption of warm perfusion than previously
accounted for. Our new fair value (base case) is SEK 160 (110) per
share.

Read more and download the research update: http://bit.ly/2w6PmOb

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment
Banking. https://www.redeye.se/about/

-----------------------------------------------------------
http://news.cision.com/se/xvivo-perfusion/r/redeye-xvivo-perfusion--harv...